Vanderbilt CTTC is looking for innovative solutions across multiple sectors. For more information, view the "Industry Opportunities" document or contact the CTTC team at swapneeta.date@vanderbilt.edu or cameron.sargent@vanderbilt.edu.
Seeking: Novel Technologies to Determine Oil and Water Composition in Heavy Oil Streams
Cenovus Energy, a leading Canadian energy producer, is seeking innovative technologies to analyze the composition of heavy oil streams. They are interested in approaches that offer advantages over current methods in terms of cost, accuracy, reliability, or analysis time. The deadline for submission is November 18th, 2024
Seeking: Bitumen Beyond Combustion: Seeking Non-combustion Uses for Asphaltenes Derived from Bitumen
An integrated energy company is seeking innovative approaches to utilize asphaltenes derived from bitumen. They are interested in solutions that provide valuable end products and have clear potential for large-scale application. The deadline for this submission is November 25, 2024.
Seeking: Novel, Effective, and Differentiated Solutions for Skin Allergy Sufferers
Kenvue, the world's largest pure-play consumer health company, is seeking innovative over-the-counter solutions for atopic dermatitis, allergic/contact dermatitis, and urticaria. They aim to develop treatments that are more efficacious, faster-acting, or easier to use compared to existing products. The deadline for submission is November 25, 2024.
Seeking: Gene Therapy for Chromosomal Abnormalities
Daiichi Sankyo is seeking a partnership with a capable collaborator who can evaluate the efficacy of gene therapies targeting specific genes in chromosomal abnormalities. The primary interest is in research focused on Down syndrome (trisomy 21), but other conditions such as trisomy 13, trisomy 18, as well as 5p- and 4p- syndromes are also within the scope. Daiichi Sankyo is also interested in research focused on identifying key target genes involved in these abnormalities. The deadline for submission is November 30, 2024.
Seeking: Exploring Protease Inhibitors as Therapeutic Agents
Daiichi Sankyo is seeking a partnership with a capable collaborator who can advance the understanding of protease involvement in disease pathology and evaluate the therapeutic potential of protease inhibition. Daiichi Sankyo has established a proprietary platform for creating potent and specific protease inhibitors. The deadline for submission is November 30, 2024.
Seeking: Gene Therapy for Normalizing Repeat Sequences in Repeat Expansion Disorders
Daiichi Sankyo is seeking a partnership with a capable collaborator who can develop novel gene therapeutic technologies to selectively normalize or reduce the expression of abnormal repeat expansions. This includes approaches that utilize Adeno-Associated Virus (AAV)-derived nucleic acids, proteins (peptides), and regulatory factors to inhibit transcription or promote the degradation of repeat sequences, as well as AAV-derived genome editing technologies that have unique features regarding editing efficiency, versatility, and safety for normalizing repeat sequences. The deadline for submission is November 30, 2024.